Grail executives were upbeat on study results for the Galleri multi-cancer early detection test, while ASCO said more ...

The Galleri test failed its primary endpoint in a landmark trial, but that doesn't mean it doesn't have a big future.

Investors remain hopeful that the Galleri test can gain FDA approval and medical insurance coverage.

At least 12 of my colleagues boarded planes to the American Society of Clinical Oncology conference in Chicago last week to hear Charles Swanton of the Francis Crick Institute in London share results ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today ...

Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ...

Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon.

GRAIL’s Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and ...

Grail (NASDAQ: GRAL) is a leader in the multi-cancer early detection market (MCED), and its stock rose 20.1% in November, according to data provided by S&P Global Market Intelligence. The move comes ...

Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the New ...

GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and ...